Otsuka Pharmaceutical Co., Ltd., trading in the U.S. under the ticker OTCMKTS:OTSKY, is a global healthcare company headquartered in Tokyo, Japan. The firm’s core activities span the development, manufacturing and marketing of prescription pharmaceuticals, consumer healthcare products and nutraceuticals. Otsuka focuses its research on areas such as neuroscience, cardiovascular and renal therapies, and oncology, aiming to bring innovative treatments to patients worldwide.
Founded in 1964 by Busaburo Otsuka as a subsidiary of the Otsuka Group, the company has grown into a diversified healthcare enterprise over more than five decades. Its prescription drug portfolio includes aripiprazole (marketed under the brand Abilify) for psychiatric disorders and tolvaptan (Samsca) for hyponatremia and autosomal dominant polycystic kidney disease. In the consumer segment, Otsuka is known for electrolyte-replenishing beverages such as Pocari Sweat, as well as a range of dietary supplements and enteral nutrition products.
Otsuka maintains a global footprint with manufacturing sites, research centers and sales offices across Asia-Pacific, North America, Europe and other regions. Its international network supports clinical development, regulatory submissions and product launches, often in collaboration with local partners and specialty distributors. This global reach enables the company to address diverse patient needs and respond to emerging healthcare trends in key markets around the world.
Governed by an experienced management team with strong backgrounds in pharmaceutical science and global commercialization, Otsuka continues to invest heavily in research and development. The company’s long-term strategy emphasizes innovation, cross-sector partnerships and sustainable growth, all aimed at delivering novel therapies and improving quality of life for patients across multiple therapeutic areas.
AI Generated. May Contain Errors.
